p38-Mediated phosphorylation of Eps15 endocytic adaptor protein  by Zhou, Yue et al.
FEBS Letters 588 (2014) 131–137journal homepage: www.FEBSLetters .orgp38-Mediated phosphorylation of Eps15 endocytic adaptor protein0014-5793/$36.00  2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
http://dx.doi.org/10.1016/j.febslet.2013.11.020
Abbreviations: CME, clathrin-mediated endocytosis; EGFR, epidermal growth
factor receptor; Eps15, EGFR pathway substrate 15; TAK1, transforming growth
factor-b-activated kinase 1; TAB1, TAK1-binding protein 1; TNF-a, tumor necrosis
factor-a; UIM, ubiquitin-interacting motif
⇑ Corresponding author. Fax: +81 76 434 7520.
E-mail address: hsakurai@pha.u-toyama.ac.jp (H. Sakurai).Yue Zhou a, Tomohiro Tanaka a, Naoyuki Sugiyama b, Satoru Yokoyama c, Yuki Kawasaki a,
Tsutomu Sakuma a, Yasushi Ishihama b, Ikuo Saiki c, Hiroaki Sakurai a,⇑
aDepartment of Cancer Cell Biology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama 930-0194, Japan
bDepartment of Molecular & Cellular BioAnalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan
cDivision of Pathogenic Biochemistry, Institute of Natural Medicine, University of Toyama, Toyama 930-0194, Japan
a r t i c l e i n f oArticle history:
Received 30 July 2013
Revised 12 November 2013
Accepted 12 November 2013
Available online 21 November 2013
Edited by Angel Nebreda
Keywords:
Eps15
TNF-a
TAK1
EGF
p38a b s t r a c t
Epidermal growth factor receptor pathway substrate 15 (Eps15) has been suggested to be involved in
the endocytosis of cell surface receptors, including epidermal growth factor receptor (EGFR). Eps15
is phosphorylated at Tyr-849 upon stimulation with EGF during endocytic processes. In the present
study, we found that stimulation of HeLa cells with EGF or TNF-a induced transient phosphorylation
of Eps15 at Ser-796. Inhibition of p38 completely blocked phosphorylation and recombinant p38a
directly phosphorylated the residue. These results demonstrate a novel stress kinase-mediated
signaling pathway to Eps15 endocytic adapter protein.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction kinase-independent manner [5–8]. p38-Mediated serine phosphor-Endocytosis of cell surface receptors is a key cellular event that
modulates intracellular signal transduction [1]. Clathrin-mediated
endocytosis (CME) is the most characterized mechanism of recep-
tor internalization. Many adaptor proteins associate with clathrin
during receptor endocytosis, helping to provide signaling speciﬁc-
ity of the endocytosed receptors. Ubiqutination of the cargo is
another critical modiﬁcation determining the endocytic
mechanism and the intracellular fate of the receptor for lysosomal
degradation or recycling to the plasma membrane [2,3].
Ligand-bound and tyrosine phosphorylated epidermal growth
factor receptor (EGFR) recruits Grb2 and Cbl E3 ubiqutin ligase [4].
Ubiquitinated EGFR is recognized by endocytic adaptor proteins,
including EGFR pathway substrate 15 (Eps15) and epsin in clath-
rin-coated pits. These proteins are further associated with adaptor
protein complex2 (AP-2) andclathrinheavychain.Wehave recently
demonstrated that pro-inﬂammatory cytokine TNF-a induced the
phosphorylation of serine and threonine residues via TAK1-p38
and TAK1-ERK pathways, respectively, in an EGFR tyrosineylation offers an alternative pathway for the CME of EGFR.
Eps15 is involved in internalization of a large variety of ligand-
inducible receptors, and also is utilized by viruses to enter host
cells [9,10]. Eps15 contains several interactive structural domains:
three N-terminal Eps15-homology (EH) domains that bind to the
asparagine–proline–phenylalanine (NPF) motifs; two C-terminal
ubiquitin-interacting motifs (UIMs) that are necessary for intra-
and intermolecular interactions with ubiquitin. It has been demon-
strated that Tyr-849 phosphorylation of Eps15 partly controls
highly concentrated ligand-induced internalization of EGFR [11].
In the present study, we addressed TNF-a-mediated phosphoryla-
tion of Eps15 and found that TNF-a promotes the phosphorylation
of Eps15 at Ser-796 via the p38 MAPK pathway. Ser-796 is also
phosphorylated by other stimuli, including EGF, osmotic stress
and an anti-cancer agent.
2. Materials and methods
2.1. Antibodies and reagents
A novel anti-phospho-Eps15 at Ser-796 (pEps15) antibody was
generated by immunizing rabbits with a synthetic phospho-pep-
tide corresponding to amino acids 789–803 of human Eps15. The
sequence of peptide antigen is as follows: NH2–RSINKLD[pS]
PDPFKLN–COOH. The immunoglobulin fraction was puriﬁed by
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phospho-speciﬁc antibody was obtained from the ﬂow-through
fraction of an unphosphorylated peptide column. Other phospho-
speciﬁc antibodies against p38 (Thr-180/Tyr-182), JNK (Thr-183/
Tyr-185), ERK (Thr-202/Tyr-204), and EGFR (Thr-669, Ser-1046/7,
Tyr-1068) were purchased from Cell Signaling Technology
(Danvers, MA, USA). Antibodies against Eps15 (K-15), p38 (C-20),
ERK1 (C-16), EGFR (1005), TAK1 (M-579), and a-tubulin (B-7) were
obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Re-
combinant human TNF-a, IL-1b, and EGF were obtained from R&D
Systems (Minneapolis, MN, USA) and recombinant human active
GST-p38a protein was from Carna Biosciences (Kobe, Japan). Cis-
platin, Phos-tag ligand, and Lys-C were from Wako Pure Chemical
Industries (Osaka, Japan); sequence-grade modiﬁed trypsin was
from Promega (Madison, WI, USA); and SB203580, SP600125,
U0126, and PD153035 were from Merck Biosciences (Darmstadt,
Germany). All of the chemical inhibitors were dissolved in Me2SO,
and the ﬁnal concentration of Me2SO was <0.1%.
2.2. Cell cultures
HeLa and HEK293 cells were maintained in Dulbecco’s modiﬁed
Eagle’s medium (high-glucose condition) supplemented with 10%
fetal calf serum, 100 U/ml penicillin, and 100 lg/ml streptomycin
at 37 C in 5% CO2. A549 cells were maintained in RPMI 1640 med-
ium supplemented with 10% fetal calf serum, 100 U/ml penicillin,
and 100 lg/ml streptomycin at 37 C in 5% CO2.
2.3. NanoLC–MS/MS analysis
Stable isotope-labeled HeLa cell pellets were suspended in lysis
buffer (20 mM HEPES/NaOH (pH 7.4), 0.25 M sucrose, 1.5 mM
MgCl2, 10 mM KCl. 0.05% NP-40, phosphatase inhibitor mixture 1,
2, and phosphatase inhibitor mixture (Sigma–Aldrich, St. Louis,
MO, USA)). After sonication, solubilization buffer (0.1 M Tris–HCl
(pH 9.0), 8 M urea and 4% octylglycoside) was added to the super-
natant. The suspension was reduced with DTT, alkylated with iodo-
acetamide, and digested with Lys-C, followed by dilution and
trypsin digestion. These digested samples were desalted using
StageTips with C18 Empore disk membranes. Enrichment of phos-
pho-peptides with metal oxide chromatography using lactic acid-
modiﬁed titania, nanoLC–MS/MS analysis and database searching
were performed as described [12–15].
2.4. Transfection of plasmid DNAs
Expression vector for GFP-Eps15 was provided by Dr. Alexandre
Benmerah (INSERM U1016, Institut Cochin, Paris, France) and de-
scribed previously [16,17]. HeLa cells were transfected using Lipo-
fectamine reagent (Life Technologies Corporation, Carlsbad, CA
USA). At 24 h post-transfection, the cells were stimulated.
2.5. RNA interference
Small interfering RNAs (siRNAs) were synthesized at Hokkaido
System Science Co., Ltd. (Hokkaido, Japan) or Life Technologies Cor-
poration (Stealth RNA interference). The target sequences were as
follows: UGGCUUAUCUUACACUGGA (TAK1), AGUAGUUCAGGAC
UACUUCUUGCUG (Eps15-1), GCCCAGCUCUCUCUGACACAGUUAU
(Eps15-2), TCACACAGGGTTCCTGACAGAATAT (ERK2), GCAUUA-
CAACCAGACAGUUGAUAUU (p38a) and CGUACGCGGAAUACUUC-
GA (ﬁreﬂy luciferase GL2). HeLa cells were transfected with
siRNAs in a ﬁnal concentration of 20 to 100 nM using Lipofect-
amine reagent. At 72 h post-transfection, the cells were stimulated.2.6. Immunoblotting
After transfection or stimulation, whole cell lysates were
prepared with lysis buffer (25 mM HEPES, pH 7.7, 0.3 M NaCl,
1.5 mM MgCl2, 0.2 mM EDTA, 0.1% Triton X-100, 20 mM
b-glycerophosphate, 1 mM sodium orthovanadate, 1 mM phenyl-
methylsulfonyl ﬂuoride, 1 mM dithiothreitol, 10 lg/ml aprotinin,
and 10 lg/ml leupeptin). Lysates were mixed with the same
volume of SDS–PAGE sample buffer (100 mM Tris–HCl (pH 6.8),
2.0% SDS, 70 mM DTT, 10% glycerol, and 0.10% bromphenol blue)
and heated at 95 C for 5 min. Samples were resolved by 6.5, 7.5
or 10% SDS–PAGE and transferred to an Immobilon-P nylon mem-
brane (Millipore, Billerica, MA, USA). The membrane was treated
with BlockAce (Dainippon Sumitomo Pharmaceutical Co., Ltd., Osa-
ka, Japan) and probed with primary antibodies. The antibodies
were detected using horseradish peroxidase-conjugated anti-rab-
bit, anti-mouse, and anti-goat IgG (DAKO, Glostrup, Denmark)
and visualized with the ECL system (GE Healthcare Bioscience, Pis-
cataway, NJ, USA). Some antibody reactions were carried out in Can
Get Signal solution (TOYOBO, Tokyo, Japan).
2.7. Zn2+-Phos-tag SDS–PAGE
After stimulation, whole cell lysates were prepared with RIPA
buffer (50 mM Tris–HCl (pH 7.4), 0.15 M NaCl, 0.25% sodium
deoxycholate, 1.0% Nonidet P-40, 1.0 mM EDTA, 20 mM b-glycero-
phosphate, 1 mM sodium orthovanadate, 1 mM phenylmethylsul-
fonyl ﬂuoride, 1 mM dithiothreitol, 10 lg/ml aprotinin, and
10 lg/ml leupeptin). Each sample was mixed with a half volume
of SDS–PAGE sample buffer (195 mM Tris–HCl (pH 6.8), 3.0% SDS,
15% 2-mercaptoethanol, 30% glycerol, and 0.10% bromphenol blue)
and heated at 95 C for 5 min. The procedures for Zn2+-Phos-tag
SDS–PAGE were described previously [18]. In brief, the acrylamide
pendant Phos-tag ligand and two quivalents of Zn(NO3)2 were
added to the separating gel before polymerization. The running
buffer consisted of 100 mM Tris and 100 mM MOPS containing
0.10% SDS and 5.0 mM sodium bisulﬁte. After Zn2+-Phos-tag SDS–
PAGE, the gel was soaked in a solution containing 25 mM Tris,
192 mM glycine, 10% MeOH, and 1.0 mM EDTA for 20 min and then
soaked in a solution containing 25 mM Tris, 192 mM glycine, and
10% MeOH for 20 min. Gel transfer, blocking, antibody reaction,
and detection were the same methods as for immunoblotting.
2.8. Immunoprecipitation
Cell lysates were diluted with an equal volume of dilution buf-
fer (20 mM HEPES pH 7.7, 2.5 mM MgCl2, 0.1 mM EDTA, 0.05% Tri-
ton X-100, 20 mM b-glycerophosphate, 1 mM sodium
orthovanadate, 1 mM PMSF, 1 mM DTT, 10 lg/ml aprotinin, and
10 lg/ml leupeptin). After centrifugation, lysates were incubated
with antibodies on ice for 1.5 h and then rotated with Dynabeads
protein G (Life Technologies Corporation) at 4 C for 1.5 h. The
beads were washed three times with wash buffer (1:1 mixture of
whole cell lysate buffer and dilution buffer).
2.9. In vitro kinase assay
Immunoprecipitated Eps15 from HEK293 cells was reacted with
recombinant human active GST-p38a at 30 C for 30 min in 30 ll
reaction buffer containing 20 mM HEPES (pH 7.6), 20 mM MgCl2,
0.2 mM ATP, 2 mM DTT, 20 mM b-glycerophosphate, 0.1 mM so-
dium orthovanadate. After stopping the reaction by adding 30 ll
SDS–PAGE sample buffer, immunoblotting was performed as de-
scribed above.
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Fig. 1. Post-translational modiﬁcation of Eps15 is induced by EGF and TNF-a. (A)
HeLa cells were stimulated with 10 ng/ml EGF or 20 ng/ml TNF-a for 10 min. Whole
cell lysates were immunoblotted with anti-Eps15 antibody. (B) Cells were stimu-
lated with 20 ng/ml TNF-a for 0, 10, 60 min. Whole cell lysates were immunoblot-
ted with anti-Eps15 antibody. (C) Whole cell lysates from cells treated with 10 ng/
ml EGF or 20 ng/ml TNF-a for 10 min were separated by Zn2+-Phos-tag SDS–PAGE
and immunoblotted with anti-Eps15 antibody.
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3.1. Post-translational modiﬁcation of Eps15 uopn TNF-a and EGF
stimulation
To determine if an inﬂammatory signal induces the post-trans-
lational modiﬁcation of Eps15, HeLa cells were stimulated withB
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luciferase (Luc). At 72 h post-transfection, cells were stimulated with 20 ng/ml TNF-a fo
antibodies.TNF-a or EGF. The mobility of the Eps15 band the SDS–PAGE was
slightly shifted by both stimulations, indicating that the post-
translational modiﬁcations of Eps15 were also promoted by
inﬂammatory cytokine (Fig. 1A). Upon TNF-a stimulation, the
band-shift was slightly induced by 10 min and had disappeared
completely by 60 min (Fig. 1B). We next performed Zn2+-Phos-
tag SDS–PAGE, an application for detection of phosphorylated pro-
teins [18]. Several shifted bands of Eps15 were detected, especially
in TNF-a-stimulated cells (Fig. 1C). Together, these results demon-
strated that TNF-a and EGF induce the phosphorylation of Eps15.
3.2. Identiﬁcation of Ser-796 as an Eps15 phosphorylation site
To identify the phosphorylation sites in Eps15, we used a na-
noLC–MS/MS system to analyze peptides derived from TNF-a-stim-
ulated HeLa cells. One candidate phospho-peptide containing the
phosphorylation of Ser-796, LD[pS]PDPFK, was detected, which is
located between AP-2 binding region and two UIMs in Eps15
(Fig. 2A–C). We next developed a phospho-speciﬁc antibody recog-
nizing this phosphorylated Eps15 to characterize the physiological
regulation of Eps15 phosphorylation. Initially, we tried to detect
Ser-796 phosphorylation of Eps15 in a transient transfection exper-
iment using GFP-Eps15 expression plasmid. TNF-a promoted the
phosphorylation of not only exogenous GFP-fused Eps15 but also45
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TAK1, a key kinase in the TNF-a signaling pathway, promoted the
expression of Eps15 phosphorylated at Ser-796 (pEps15) (data not
shown). In order to conﬁrm the speciﬁcity of the antibody, immuno-
blotting was performed in the presence of non-phospho-peptide or
Ser-796-phosphorylatied peptide. Phospho-peptide, but not non-
phospho-peptide, completely blocked the antibody binding to
phosphorylated Eps15 (Fig. 2E). In addition, siRNA-mediated knock-
down of Eps15 decreased the phosphorylation band (Fig. 2F). These
results clearly demonstrated that TNF-a induces the phosphoryla-
tion of Eps15 at Ser-796 and the phospho-Eps15 antibody
speciﬁcally recognizes phosphorylated Eps15.
3.3. Phosphorylation of Eps15 is promoted by various stimuli
To investigate the time course of pEps15, HeLa cells were stim-
ulated with TNF-a. As shown in Fig. 3A, pEps15 was induced from
3 min, peaked during 10–20 min, and was signiﬁcantly downregu-
lated at 60 min, which closely correlated with the time course of
Ser-1046/1047 phosphorylation of EGFR (pS-EGFR) and phospho-
p38. In our previous report, pS-EGFR was promoted by the activa-
tion of p38 [7], which strongly suggests that p38 is involved in both
pEps15 and pS-EGFR (Fig. 3A).
We next tried to examine the effects of other various stimuli
which promote the activation of p38. HeLa cells were treated with
EGF, high osmotic stress (0.3 M NaCl), and a DNA-damaging agent,
cisplatin. As expected, pEps15 was strongly induced by all the
agents (Fig. 3B and C). In addition, pEps15 was induced by TNF-a
and IL-1b in human lung cancer A549 cells, elucidating that Ser-
796 is a common phosphorylation site induced by an inﬂammatory
signal in different cell lines (Fig. 3D). Together, our resultsA
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Fig. 3. Phosphorylation of Eps15 at Ser-796 is induced by various stimulations. (A) HeLa
were stimulated with 10 ng/ml EGF or 0.3 M NaCl for the periods indicated. (C) HeLa cell
with 20 ng/ml TNF-a or 10 ng/ml IL-1b for 10 min. Whole cell lysates were immunoblot
anti-phospho-ERK, anti-ERK, anti-phospho-p38, anti-p38, and anti-a-Tubulin antibodiesidentiﬁed a new inducible phosphorylation site of Eps15 under
physiological conditions.
3.4. Characterization of signaling pathway leading to Eps15
phosphorylation
To identify the kinases responsible for pEps15, HeLa cells were
pre-treated with TAK1 inhibitor (5Z-7-oxozeanol) or EGFR tyrosine
kinase (TK) inhibitor (PD153035). PD153035, but not 5Z-7-oxoze-
anol, inhibited EGF-induced activation of MAPKs, but TNF-a-in-
duced MAPK activation was selectively inhibited by only 5Z-7-
oxozeanol. Similarly, these inhibitors selectively disrupted pEps15
in a stimulus-dependent fashion (Fig. 4A). RNAi experiment using
siRNA against TAK1 demonstrated the involvement of the TAK1
pathway in TNF-a-induced phosphorylation of Eps15 (Fig. 4B). To
further investigate the role of downstream kinases, cells were trea-
ted with TNF-a or EGF in the presence of chemical inhibitors of
MAPKs; p38, JNK and ERK. Similar to pS-EGFR, pEps15 was abro-
gated by only p38 inhibitor (SB203580), but not by JNK inhibitor
(SP600125) or ERK inhibitor (U0126) (Fig. 4C and D). RNAi-medi-
ated knockdown of p38a, but not ERK2, also impaired pEps15
(Fig. 4E), indicating that the p38 pathway is fundamental to pro-
moting the phosphorylation of Eps15 at Ser-796.
The phosphorylation site of human Eps15 (phospho-Ser-Pro) is
completely matched to the consensus sequence of p38 substrates
(Ser/Thr-Pro) [19]. Therefore, to obtain direct evidence for p38a
phosphorylation of Eps15, we performed an in vitro kinase assay
and found that recombinant active p38a could phosphorylate
immunoprecipitated Eps15 from HEK293 cells (Fig. 4F). Collec-
tively, these results demonstrated that phosphorylation of Ser-
796 is catalyzed by p38 directly.C60
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Endocytosis has a complicating mechanism to regulate receptor
signaling and transport of substances across the plasma membrane
[1–4]. Eps15 is one of the important adaptor molecules participat-
ing in CME [8,9]. In this study, we identiﬁed a novel phosphoryla-
tion site of Eps15 by p38. The phospho-acceptor serine
corresponding to Ser-796 of human Eps15 is conserved in otherPrimates,Mus musculus, and Rattus norvegicus, and has been depos-
ited as a phosphorylation site in the public phosphorylation data-
base; however, a proline residue important for p38 recognition is
conserved in only Catarrhini [20]. Therefore, it should be addressed
whether p38 is the kinase catalyzing phosphorylation of the
conserved serine residue in these species.
It has been reported that Eps15 interacts with AP-2 through
amino acids 666–737 and Grb2 around Pro-768 [21–24]. Ser-796
136 Y. Zhou et al. / FEBS Letters 588 (2014) 131–137is located between Grb2-/AP-2-binding domains and the C-termi-
nal UIM domain (see Fig. 2A), suggesting an important role in
CME. One of the most characterized cargos of CME is the EGFR
[4]. Earlier studies have shown that Eps15 at Tyr-849 is phosphor-
ylated in EGF-stimulated cells and partly controls the internaliza-
tion of mono-ubiquitinated EGFR via UIM domains of Eps15 [10].
It has also been shown that active EGFR phosphorylates Tyr-849
directly; however, we could detect no tyrosine-phosphorylated
Eps15 band or phospho-tyrosine-containing peptide in immuno-
blotting and nanoLC-MS/MS analysis, respectively (data not
shown). We have recently reported that EGFR is internalized by
CME in a tyrosine kinase-independent and p38-mediated fashion
[5–7]. These results suggest an attractive model in which p38
phosphorylates both Eps15 and EGFR to trigger efﬁcient endocyto-
sis; however, we could obtain no direct evidence for the role of
Eps15 in TNF-a-induced EGFR endocytosis, even in triple (Eps15
and its functionally redundant proteins, epsin 1 and Eps15R)
knocked-down HeLa cells (Supplementary Figs. 1 and 2) [25]. This
is supported by a recent ﬁnding that Eps15 is dispensable for EGFR
endocytosis in Eps15-deﬁcient mouse ﬁbroblasts [26].
It has been reported that Eps15 participates in the endocytosis
of other proteins, including MET, transferrin, and integrin b1, and is
also involved in infectious entry of viruses [20,27–32]. AMPA
receptor, Platelet-activating factor receptor and mu-opioid recep-
tor require p38 for their endocytosis [33–35]. In addition, Eps15
can act as a novel autophagy adaptor molecule [36]. Facing starva-
tion, cells degrade the gap junction, in which Eps15 associates with
ubiquitinated connexin 43 [37,38]. This recruits autophagic
machinery to internalize connexin 43 and leads to lysosomal deg-
radation. Moreover, Pozzi et al. recently reported a new function of
Eps15 using Eps15-KOmice in which Eps15 controls marginal zone
(MZ) B cell numbers [26]. It is therefore necessary to elucidate the
physiological functions of Eps15 and its phosphorylation at Ser-
796, especially in relation to the activation of p38, which will pro-
vide new insight into the physiological functions of Eps15.
In summary, we have identiﬁed that p38 directly phosphory-
lates Ser-796 of Eps15. This ﬁnding is a key to open a new window
to address the role of Eps15 endocytic adaptor protein. A
phospho-speciﬁc Eps15 antibody is a powerful tool for future char-
acterization of Eps15 under physiological and pathophysiological
conditions, including inﬂamed tissues, such as tumor
microenvironments.
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